Polymeric Micellar Co-delivery of Resveratrol and Curcumin to Mitigate In Vitro Doxorubicin-Induced Cardiotoxicity

Torres, 2012, Doxorubicin-induced oxidative injury of cardiomyocytes—Do we have right strategies for prevention Deres, 2005, Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound, J Cardiovasc Pharmacol, 45, 36, 10.1097/00005344-200501000-00007 Zhu, 2009, Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway, Circulation, 119, 99, 10.1161/CIRCULATIONAHA.108.799700 Baur, 2006, Therapeutic potential of resveratrol: The in vivo evidence, Nat Rev Drug Discov, 5, 493, 10.1038/nrd2060 Li, 2006, Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress, Pharmacol Res, 53, 6, 10.1016/j.phrs.2005.08.002 Vinod, 2013, Phytochemicals as chemosensitizers: From molecular mechanism to clinical significance, Antioxid Redox Signal, 18, 1307, 10.1089/ars.2012.4573 Liu, 2012, Increasing solubility of poorly water soluble drug resveratrol by surfactants and cyclodextrins, Adv Mat Res, 418–420, 2231 Walle, 2011, Bioavailability of resveratrol, Ann N Y Acad Sci, 1215, 9, 10.1111/j.1749-6632.2010.05842.x Kurien, 2007, Improving the solubility and pharmacological efficacy of curcumin by heat treatment, Assay Drug Dev Technol, 5, 567, 10.1089/adt.2007.064 Kabanov, 2002, Pluronic block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers, Crit Rev Ther Drug Carrier Syst, 19, 1, 10.1615/CritRevTherDrugCarrierSyst.v19.i1.10 Shin, 2009, Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs, J Control Release, 140, 294, 10.1016/j.jconrel.2009.04.024 Oerlemans, 2010, Polymeri micelles in anticancer therapy: Targeting, imaging and triggered release, Pharm Res, 27, 2569, 10.1007/s11095-010-0233-4 Wu, 2011, Resveratrol: A cardioprotective substance, Ann N Y Acad Sci, 1215, 16, 10.1111/j.1749-6632.2010.05854.x Stammet, 2010, Drug loading in pluronic(R) micelles made by solvent casting and equilibrium methods using resveratrol as a model drug, J Control Release, 148, e50, 10.1016/j.jconrel.2010.07.056 Ur-Rehman, 2010, Effect of DMSO on micellization, gelation and drug release profile of Poloxamer 407, Int J Pharm, 394, 92, 10.1016/j.ijpharm.2010.05.012 Chou, 2010, Drug combination studies and their synergy quantification using the Chou-Talalay method, Cancer Res, 70, 440, 10.1158/0008-5472.CAN-09-1947 Chu, 2005, Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1, Cancer Res, 65, 10183, 10.1158/0008-5472.CAN-05-2002 Iqbal, 2012, Resveratrol inhibits cancer cell metabolism by down regulating pyruvate kinase M2 via inhibition of mammalian target of rapamycin, PLoS One, 7, e36764, 10.1371/journal.pone.0036764 Singh, 2009, Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells, Mol Cell Biochem, 325, 107, 10.1007/s11010-009-0025-5 Csaki, 2009, Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: Inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis, Arthritis Res Ther, 11, R165, 10.1186/ar2850 Olsson, 2011, Caspases and cancer, Cell Death Differ, 18, 1441, 10.1038/cdd.2011.30 Halliwell, 2004, Measuring reactive species and oxidative damage in vivo and in cell culture: How should you do it and what do the results mean, Br J Pharmacol, 142, 231, 10.1038/sj.bjp.0705776 Fiers, 1999, More than one way to die: Apoptosis, necrosis and reactive oxygen damage, Oncogene, 18, 7719, 10.1038/sj.onc.1203249